Wellington Management Group LLP Acquires New Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Wellington Management Group LLP purchased a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 68,024 shares of the biopharmaceutical company's stock, valued at approximately $758,000. Wellington Management Group LLP owned 0.05% of Dynavax Technologies as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 1,172 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 1,679 shares during the period. GAMMA Investing LLC grew its stake in shares of Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 1,685 shares in the last quarter. Louisiana State Employees Retirement System increased its position in Dynavax Technologies by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company's stock worth $740,000 after acquiring an additional 1,900 shares during the period. Finally, US Bancorp DE raised its stake in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,034 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX traded down $0.04 during trading on Friday, reaching $12.72. 4,031,312 shares of the company traded hands, compared to its average volume of 2,119,194. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $15.01. The firm has a market capitalization of $1.67 billion, a PE ratio of 97.85 and a beta of 1.33. The company's 50 day moving average is $12.20 and its two-hundred day moving average is $11.52.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.